retatrutide clinical trials results weight loss Lilly orforglipron oral GLP-1 phase 3 trial Retatrutide Shows 28% Weight Loss
Description
7376 Table 2 summarizes the key studies, their populations, and main findings
Further, 10 % of weight reduction ameliorated steatosis and lobular inflammation in all patients and ballooning in 90 % of patients [39]
Neuroinflammation reduction
doi: 10.1016/j.expneurol.2013.11.001 [DOI] [PubMed] [Google Scholar] 182.Marxreiter F, Regensburger M, Winkler J
GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet
